Market Research Report
Global Peptide Therapeutics Market - 2022-2029
|Global Peptide Therapeutics Market - 2022-2029|
Published: June 3, 2022
Content info: 190 Pages
Delivery time: 2 business days
The Global "Peptide Therapeutics Market" is expected to grow at a CAGR of 8% during the forecasting period (2022-2029).
Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs), and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options.
The global peptide therapeutics market growth is driven by the rising prevalence of infectious diseases, cancer, and metabolic diseases such as obesity, diabetes, and osteoporosis, coupled with the growing demand for effective drugs.
The increasing prevalence of cancer and metabolic disorders will drive the market growth
The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes.
In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market.
Peptide therapeutics companies have come to appreciate the role that peptide pharmaceuticals can play in addressing unmet medical needs, and how this class of compounds can be an excellent complement or even a preferable alternative to small molecule and biological therapeutics, resulting in a revival of interest and scientific momentum in peptide drug discovery over the last decade.
The geriatric population is more prone to various chronic conditions, and the surge in the old age population across the globe is anticipated to drive the growth of the global peptide therapeutics market. 85 years and older, is the fastest-growing population group in the United States. According to Cancer Facts & Figures 2019, the estimated number of older adults aged 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060. In 2019, 1,944,280 adults ages 85 and older were alive with a history of cancer.
The purification of long peptides has been a major challenge that will hamper the growth of the market
However, the purification of long peptides has been a major challenge, with a limited capacity of solid-phase reactors for chemical functionalization along with swelling of the resins. The rise in modifications and the addition of more unnatural amino acids have made the synthesis more complex. However, recent advances in bioprocess & fermentation technologies for therapeutic peptide production such as modular & flexible factories and single-use production systems are likely to mitigate this threat
COVID-19 Impact Analysis
Novel peptides are being developed and repurposed as therapeutics for the treatment of COVID-19. Globally, researchers continue to search for compounds that either block the mechanisms important for SARS-CoV-2 infection and replication or treat conditions caused by the infection. On February 21, 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As of May 2020, there were 21 peptide drugs for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection.
Hence, COVID-19 may have a positive impact on the peptide therapeutics market as peptide drugs are being considered as a treatment option for dealing with COVID-19. However, the current applications of peptide therapeutics in oncology, metabolic disorders, etc., have been disrupted due to a shortage of drugs and supply chain issues, along with the slow progress of clinical trials related to non-COVID-19 therapeutics.
The cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.
According to the International Agency Research on Cancer- GLOBOCAN 2020 report, a total of 19,292,789 new cancer cases were diagnosed worldwide in 2020, with 9,958,133 deaths due to cancer. Also, the five-year prevalent cases of cancer were estimated to be 50,550,287 globally. The number of new cancer cases is expected to reach 28,887,940 by 2040 worldwide. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor in the growing focus on alternative therapeutics such as peptide-based drugs.
The North American region holds the largest market share of the global peptide therapeutics market
North America dominates the market for peptide therapeutics and is expected to show a similar trend over the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry.
The increasing research and development expenditure by governments and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. According to the estimates of the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases were diagnosed, and 606,520 cancer deaths were reported in the United States. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.
The peptide therapeutics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, and Novo Nordisk AS among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the peptide therapeutics market globally. For instance, in May 2021, ISSAR Pharmaceuticals took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma. The company was formerly known as Bristol-Myers Company.
EMPLICITI: EMPLICITI in combination with REVLIMID and dexamethasone or in combination with POMALYST and dexamethasone may cause the following serious side effects. Infusion reactions, infections, risk of developing new cancers (malignancies), and liver problems. There are also other serious risks (Boxed WARNINGS) associated with REVLIMID and POMALYST.
Visualize the composition of the global peptide therapeutics market segmentation by type, application, route of administration, and region highlighting the key commercial assets and players.
Identify commercial opportunities in the global peptide therapeutics market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global peptide therapeutics market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global peptide therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190.
LIST NOT EXHAUSTIVE